Global Infertility Market 2015-2019
Infertility is a widespread problem, and it is the inability to conceive after having regular unprotected sex. In one-third of the cases, infertility is because of either female infertility factors or male infertility factors. In rest of the cases, the cause is either unknown or a combination of both male and female factors. In males, infertility is due to a couple of factors including low sperm production, abnormal sperm function, or blockages that prevent the delivery of sperm. The cause of infertility can be difficult to diagnose, but many treatments are available. Treatment options depend on underlying problems.
TechNavio's analysts forecast the Global Infertility market to grow at a CAGR of 4.52 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Infertility market for the period 2015-2019. The Global Infertility market can be divided into two segments: Infertility Drugs and Infertility Devices. To calculate the market size, the report considers revenue generated from the sales of various drugs and devices used in the treatment of infertility.
TechNavio's report, the Global Infertility Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Infertility market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
TechNavio Announces the Publication of its Research Report – Global Infertility Market 2015-2019
TechNavio recognizes the following companies as the key players in the Global Infertility Market: Bayer HealthCare AG, CooperSurgical Inc., Ferring Pharmaceuticals Inc. and Merck & Co. Inc.
Other Prominent Vendors in the market are: Abbott Laboratories, AbbVie, Actavis, Apricus Biosciences, AstraZeneca, Bristol-Myers Squibb, Dong-A Socio, Elelixis Diagnostics, Eli Lilly, HRA Pharma, Invo Bioscience, Halotech DNA, Medical Electronic Systems, Novartis, Pfizer, PregLem, Sanofi and Vivus.
Commenting on the report, an analyst from TechNavio’s team said: “One key trend emerging in this market is the increased awareness. With the increase in public awareness, the acceptability of infertility treatment options is also expected to increase. For instance, a division of Reproductive Endocrinology and Infertility has been associated with new and innovative approaches for the management of infertility.”
According to the report, one of the main drivers of this market is the increase in age-related infertility. With age, sperm motility declines in men, while in women the capability to conceive diminishes because of natural factors. Media coverage of infertile couples and infertility treatments has made couples more aware of infertility treatment options.
Further, the report states that one of the main challenges that the market faces is the patent expiry of major blockbuster drugs and the entry of generics. The entry of generics is expected to have a negative impact on the revenue of branded drugs that are expected to be launched during the forecast period of 2014-2019.
Bayer Healthcare , CooperSurgical, Ferring Pharmaceuticals, Merck & Co., Abbott Laboratories, AbbVie, Actavis, Apricus Biosciences, AstraZeneca, Bristol-Myers Squibb, Dong-A Socio, Elelixis Diagnostics, Eli Lily, Halotech DNA, HRA Pharma, InvoBioscience, Medical Electronic Systems, Novartis, Pfizer, PregLem, Sanofi, Vivus